Moderna has reported the first profitable quarter in the company’s history: after 10 years of research and several billion dollars of investment in its mRNA platform. The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month. Total revenue for the company was $1.9bn in Q1 (three months ended March 31, 2021): compared to $8m for the same period in 2020. Net income was $1.2bn for the quarter, compared to a net loss of $124m the year before. Sales for 2021 are projected to total $19.2 billion. And looking forward, Moderna predicts that 2022 COVID-19 vaccine sales will exceed 2021’s sales.